Browse articles from EyeWorld.org related to AMD. EyeWorld is the award-winning member publication of ASCRS. The magazine provides news and updates from the Society as well as clinical features in the areas of cataract, refractive, cornea, glaucoma, and practice management. It publishes quarterly with editorial direction from its medical editorial board and staff.
➤ FDA approves twice-daily use of presbyopia drop
➤ Study: drug approved for high blood pressure shows promise for blinding childhood disease
➤ Breakthrough device designation granted to investigational dry AMD therapy
➤ Positive topline results for Phase 2 study of retinitis pigmentosa treatment
➤ FDA approves pediatric enrollment in trial for retinitis pigmentosa and Leber congenital amaurosis
➤ ASCRS news and events
➤ Patient enrollment complete for sustained release AMD therapy trial
➤ First patient dosed with corneal endothelial cell substitute
➤ First patient dosed in RNAi therapy for wet and dry AMD
➤ Study: early signs of corneal graft rejection reversed with steroid nanoparticle
➤ Company announces anti-VEGF market tracker
➤ ASCRS news and events
➤ ASCRS EyeWorld Weekly: View the current issue
➤ Allogenic cell therapy receives regulatory approval for bullous keratopathy indication
➤ 24-month data on AMD photobiomodulation therapy
➤ Patient enrollment complete for Phase 3 trial evaluating topical presbyopia treatment
➤ Pre-IND meeting for treatment of corneal endothelial disease
➤ IND submitted for geographic atrophy treatment
➤ Second Phase 3 trial for dry eye disease therapy
➤ ASCRS news and events
➤ NDA submitted for sustained-release travoprost implant
➤ BLA for wet AMD, DME, DR treatment accepted with priority review
➤ Topline results from 12-month safety clinical trial for investigational dry eye drug
➤ Companies collaborate for research on sustained release for investigational GA drug
➤ ASCRS news and events
➤ First FDA-approved treatment for geographic atrophy
➤ FDA accepts NDA for presbyopia drop
➤ NDA for geographic atrophy drug accepted with priority review
➤ Study: 5-year visual field data with MIGS device
➤ ASCRS news and events
➤ FDA approves first pharmacologic treatment of ROP for preterm infants
➤ FDA accepts NDA for dilation reversal drop
➤ Phase 2b results for anti-VEGF agent for wet AMD
➤ Interim results for Phase 1 study evaluating hydrogel implant for retinal diseases
➤ Data from ongoing Phase 1/2 clinical trial of gene therapy for Leber congenital amaurosis
➤ ASCRS news and events
➤ FDA approves treatment for subfoveal choroidal neovascularization due to AMD
➤ IND for inherited RPE clinical trial receives FDA clearance
➤ Phase 3 clinical trial to evaluate cooling device for anesthesia prior to injections
➤ Study calls ‘long-believed theory about diabetic cataracts into question’
➤ ASCRS news and events
➤ NDA submitted to FDA for drug that reverses mydriasis
➤ FDA cleared IND application for gene therapy to treat form of Leber congenital amaurosis
➤ FDA approves IND for research to move forward on RP gene therapy
➤ Phase 2 study to treat geographic atrophy begins
➤ Study: Weaning patients off of AMD treatments compared
➤ Possible geographic atrophy treatment explored
➤ ASCRS news and events
➤ Phase 1/2a results for suprachoroidal wet AMD treatment
➤ Enrollment complete for two Phase 2 trials investigating dry eye therapies disease
➤ Phase 2b study for drug-eluting contact lens begins
➤ Healthcare company acquires biopharmaceutical company developing ophthalmic treatments
➤ Development and commercialization licensing agreement
➤ ASOA podcast features dry eye info for the practice
➤ ASCRS news and events
➤ FDA accepts NDA for ‘first-of-its-kind’ anti-inflammatory for dry eye
➤ Positive Phase 3 results for investigational presbyopia therapy
➤ Study: long-term visual outcomes with remote monitoring technology
➤ Companies partner to create tool to assess fall risk
➤ ASCRS news and events
